The proposed transaction with Regeneron includes 23andMe’s personal genome service and total health and research services.

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

Biotechnology company Regeneron agreed to buy the assets of 23andMe, the DNA testing company that filed for bankruptcy in March, for $256 million. That’s just 4% of the San Francisco-based startup’s ...

Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug discovery.

Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...

The BriefGenetics testing company 23andMe on Monday announced a deal to be acquired by biotechnology company Regeneron.The ...